Table 3. Gender-stratified frequencies of malignancies and standard incidence ratios (SIR) for China, 2008 to 2011.
| Malignancy Site/Type (ICD-O-3 Code) | Males | Females | ||||
|---|---|---|---|---|---|---|
| Observed | Expecteda | SIRa (CI) | Observed | Expecteda | SIRa (CI) | |
| All Cancers | 2,808 | 832.2 | 3.4 (3.3–3.5) | 1,011 | 392.6 | 2.6 (2.4–2.7) |
| All (Excluding Ill-defined/Unspecified) | 2,524 | 809.9 | 3.1 (3.0–3.2) | 898 | 382.2 | 2.3 (2.2–2.5) |
| Ill–defined/Unspecified | 284 | 22.3 | 12.8 (11.3–14.3) | 113 | 10.4 | 10.9 (9.0–13.1) |
| AIDS-Defining Cancers (all lymphomasb) | 431 | 21.6 | 19.9 (18.1–21.9) | 284 | 40.7 | 7.0 (6.2–7.8) |
| Kaposi sarcoma (9140) | 132 | 0.05 | 2,639.8 (2,208.7–3,130.5) | 39 | 0.02 | 1,593.5 (1,133.0–2,178.4) |
| Lymphomab (959, 965) | 299 | 21.6 | 13.9 (12.3–15.5) | 117 | 7.3 | 16.0 (13.2–19.1) |
| Cervical (C53) | - | - | - | 128 | 33.4 | 3.8 (3.2–4.6) |
| Non-AIDS-Defining Cancers (no lymphomasb) | 2,377 | 810.6 | 2.9 (2.8–3.1) | 727 | 351.9 | 2.1 (1.9–2.2) |
| Oral cavity (C00–C09) | 13 | 9.9 | 1.3 (0.7–2.2) | 4 | 3.3 | 1.2 (0.3–3.1) |
| Nasopharynx (C11) | 38 | 22.9 | 1.7 (1.2–2.3) | 9 | 5.2 | 1.7 (0.8–3.3) |
| Other head and neck (C12–C14, C30–C32) | 47 | 13.6 | 3.4 (2.5–4.6) | 17 | 1.1 | 16.0 (9.3–25.6) |
| Esophagus (C15) | 78 | 62.5 | 1.2 (1.0–1.6) | 19 | 10.9 | 1.7 (1.0–2.7) |
| Stomach (C16) | 137 | 116.1 | 1.2 (1.0–1.4) | 60 | 26.7 | 2.2 (1.7–2.9) |
| Colon and rectum (C18–C20) | 121 | 81.5 | 1.5 (1.2–1.8) | 32 | 29.5 | 1.1 (0.7–1.5) |
| Anus (C21) | 2 | 0.7 | 2.9 (0.3–10.5) | 0 | 0.2 | 0.0 (0.0–19.7) |
| Liver (C22) | 539 | 138.3 | 3.9 (3.6–4.2) | 84 | 16.1 | 5.2 (4.2–6.5) |
| Other digestive system (C23, C24, C26) | 6 | 12.1 | 0.5 (0.2–1.1) | 1 | 5.3 | 0.2 (0.0–1.0) |
| Pancreas (C25) | 41 | 19.7 | 2.1 (1.5–2.8) | 2 | 6.1 | 0.3 (0.0–1.2) |
| Lung (C34) | 713 | 150.1 | 4.8 (4.4–5.1) | 140 | 33.2 | 4.2 (3.5–5.0) |
| Mediastinum and pleura (C38) | 4 | 4.9 | 0.8 (0.2–2.1) | 2 | 1.3 | 1.5 (0.2–5.5) |
| Bone (C40) | 11 | 7.0 | 1.6 (0.8–2.8) | 2 | 2.5 | 0.8 (0.1–2.8) |
| Skin (C44) | 17 | 7.5 | 2.3 (1.3–3.6) | 9 | 2.2 | 4.0 (1.8–7.7) |
| Soft tissue (C47–C49) | 5 | 4.5 | 1.1 (0.4–2.6) | 7 | 1.8 | 3.9 (1.5–8.0) |
| Breast (C50) | 2 | 1.2 | 1.6 (0.2–5.8) | 31 | 98.8 | 0.3 (0.2–0.4) |
| Vagina and vulva (C51, C52) | - | - | - | 2 | 0.9 | 2.2 (0.2–8.0) |
| Corpus uteri (C54) | - | - | - | 48 | 17.4 | 2.8 (2.0–3.7) |
| Ovary and other female genital tissue (C55–C58) | - | - | - | 5 | 18.0 | 0.3 (0.1–0.6) |
| Penis (C60) | 6 | 2.2 | 2.8 (1.0–6.1) | - | - | - |
| Prostate (C61) | 9 | 14.8 | 0.6 (0.3–1.2) | - | - | - |
| Other male genital tissue (C62, C63) | 5 | 5.0 | 1.0 (0.3–2.4) | - | - | - |
| Kidney (C64) | 10 | 20.6 | 0.5 (0.2–0.9) | 2 | 5.2 | 0.4 (0.0–1.4) |
| Other urinary system (C65–C68) | 3 | 2.7 | 1.1 (0.2–3.3) | 0 | 1.0 | 0.0 (0.0–3.5) |
| Bladder (C67) | 9 | 24.0 | 0.4 (0.2–0.7) | 1 | 2.9 | 0.4 (0.0–1.9) |
| Eye (C69) | 4 | 0.4 | 10.3 (2.8–26.4) | 3 | 0.3 | 9.6 (1.9–28.1) |
| Brain and CNS (C70, C71) | 216 | 26.4 | 8.2 (7.1–9.3) | 105 | 11.9 | 8.8 (7.2–10.7) |
| Thyroid (C73) | 2 | 17.3 | 0.1 (0.0–0.4) | 0 | 28.8 | 0.0 (0.0–0.1) |
| Multiple myeloma (C90) | 4 | 3.8 | 1.1 (0.3–2.7) | 1 | 1.3 | 0.8 (0.0–4.3) |
| Melanoma (872) | 1 | 1.6 | 0.6 (0.0–3.6) | 0 | 0.7 | 0.0 (0.0–5.2) |
| Leukemia (981) | 50 | 17.2 | 2.9 (2.2–3.8) | 28 | 8.8 | 3.2 (2.1–4.6) |
ICD-O-3: International Classification of Disease for Oncology [32], 3rd Edition, SIR: standard incidence ratio, CI: 95% confidence interval, CNS: central nervous system
aSIR is calculated using Chinese National Cancer Registry data for 2008 (Expected) [35], and CI calculated based on an assumed Poisson distribution
bBecause approximately half of lymphoma records did not specify Hodgkin or Non-Hodgkin lymphoma, combined observed and expected lymphoma figures were calculated